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Objectives: Ovarian cancer is associated with the highest mortality of gynecologic cancers. 
Epidemiological and genetic factors of ovarian cancer development are clearly defined but 
prognostic factors have not been adequately identified. Right and left ovarian cancers seem to 
act different behaviors at high-grade serous ovarian cancer (HGSOC) prognosis. The aim of 
this study is to explain this prognostic role of its sidedness. The aim of this study is to explain 
this prognostic role of its sidedness. 
Material and methods: We reviewed 160 consecutive patients with Figo stage 1-3 HGSOCs 
and undergone surgery at two high-volume hospitals. Prognostic effects of primary tumor 
location onset were evaluated in terms of 5-year disease free survival and overall survival 
rate. 
Results: One hundred-sixty patients with ovarian cancer records were analyzed using the 
Kaplan-Meier method, that demonstrated a significant difference in the 5-year disease-free 
survival rates between right and left-sided cancers for all stages (44.6% vs 78.5%, p < 0.001). 
Also, there was significant difference in the 5-year overall survival rates between the two 
groups (71.1% vs 91.9%, p = 0.020). 
Conclusions: Tumor location within the HGSOC seems to be a compelling prognostic factor 
ovarian cancer. Further prospective studies are needed in order to support our hypothesis. 
Key words: disease free survival; high-grade serous ovarian cancer; left and right side 
cancers; overall survival; prognostic values; tumor location 
 
INTRODUCTION 
Ovarian cancer is the second most common gynecologic cancer. Furthermore, it is 
associated with the highest mortality of gynecologic cancers in the western world. According 
to the results, every year, 230 000 new ovarian cancer patients will be diagnosed, and 150 000 
of those are likely to die [1]. Due to the lack of warning symptoms and the absence of 
screening recommendations, approximately 70% of cases diagnosed with advanced disease 
[2]. 
      Invasive ovarian cancers evaluated into three main types: epithelial ovarian cancers, 
sex-cord stromal tumors, and germ cell tumors. Epithelial ovarian cancers are the most 
common types and associated with aggressive behavior and a high relapse rate. Epithelial 
ovarian cancer is a heterogeneous disease with four major histologic subtypes as the serous, 
endometrioid, mucinous, and clear cell. High-grade serous ovarian cancer (HGSOC) is the 
most common (70%) and aggressive subtype of all disease [3]. At early-stage disease, patients 
have a five-year survival rate of 92%, although this rate decreases to 29% at advanced stage 
disease [4]. Also, approximately 75% of patients diagnosed at an advanced stage.  
      Embryonic left–right asymmetry causes different responses to external influences. At 
malignancies asymmetry is best described is colon cancer. Many studies reported clinical, 
pathological and in the molecular biological pattern differences between right- sided colon 
carcinomas (RCC) and left-sided colon carcinomas (LCC) [5]. The differing molecular 
characteristics translate into a differential clinical outcome with RCC displaying a poor 
prognosis [6]. Literature suggests that site of the primary tumor within the colon have 
prognostic and treatment implications. However, some studies investigated the laterality of 
cutaneous melanoma and the excess of left-sided tumors seemed to appear to statistically 
significantly more than right sided tumors. Reason of this could be differences in sun 
exposure and/or asymmetry of melanocyte distribution or characteristics arising at the time of 
embryological development [7, 8].       
      This article determines an overview of ovarian cancer and the prognostic role of its 
sidedness. Recent studies showed us lymph nodes are asymmetrical in the right and left axis 
of human; although fewer lymph nodes on the left side, they are more hypertrophic [9]. This 
study aims to evaluate the effect of lateralization of tumor side on disease-free survival (DFS) 
and overall survival (OS) rates.  
 
MATERIAL AND METHODS 
Study population 
      The database of the Medical Oncology Department of two high-volume hospitals was 
used to identify all patients diagnosed with ovarian cancer. All patients in this study 
underwent curative resection for ovarian cancer [10]. The histopathological staging was 
confirmed postoperatively by a consulting pathologist, according to The International 
Federation of Obstetrics and Gynecology (FIGO) staging system. Patients’ data were 
collected from medical records and clinical follow-up visits. Demographic characteristics of 
patients included age at diagnosis, body mass index (BMI), marital status, number of births, 
educational status, menopause status, and occupation.  
      Two hundred thirty patients with HGSOC were investigated; after analyzing the 
medical records, 160 patients were chosen according to the following inclusion criteria: (1) 
Patients with ovarian cancer originated from one side clearly; left or right (2) diagnosed as 
epithelia, high grade serous ovarian cancer, (3) staged by International Federation of 
Gynecology and Obstetrics (FIGO) as stage 1 to 3 who underwent total hysterectomy, 
salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy, omentectomy, and resected 
any suspicious or enlarged disease.  
      Patients meet the following criteria were excluded: (1) cancer that originated from 
both sides or unclear (2) patients at age under 18 (3) who had more than one solid tumor 
history (4) staged as stage 4 disease according to FIGO.  
      Parameters were evaluated as categories when through analysis, and these categories’ 
relationships with DFS and OS were examined. DFS was calculated from the date of ovarian 
cancer resection to the time of proven recurrence. OS was calculated from the date of ovarian 
cancer resection until the time of death from any cause or the last follow up time. 
     All procedures performed in studies involving human participants were in accordance 
with the ethical standards of the institutional and/or national research committee and with the 
1964 Helsinki declaration and its later amendments or comparable ethical standards; was 
approved by the Ethics Committee of The Institutional Review Board of Istanbul Medeniyet 
University Hospital local Ethics Committee (IRB No. 2020/0066). 
 
Adjuvant chemotherapy and follow up 
      The adjuvant treatment regimen contained carboplatin (AUC 5) and paclitaxel (175 
mg/m2) on day 1. This cycle was repeated every three weeks. The planned treatment duration, 
according to our standard institutional protocol was six cycles. Most patients were followed 
according to our institutional protocol, which consisted mainly of physical examination, 
measurement of the serum tumor marker [cancer antigen 125 (CA 125)], and computed 
tomography. 
      For the remaining patients, information regarding clinical outcome and survival was 
obtained by telephone interviews with the patients or their relatives. Tumor recurrence was 
detected by physical examination, serum CA 125 assay, and chest, abdominal, and pelvic 
imaging every 3–6 months for two years, and then every six months for the following three 
years [11]. After five years, patients had annual follow-up examinations unless they have an 
emerging complaint. We started analyzing patients with HGSOC retrospectively from 
December 12, 2014. The cutoff date for our analysis was July 20, 2019. 
 
Statistical methods 
      The demographic and clinicopathological features of the study population were 
stratified according to primary ovarian tumor side. Categorical variables were expressed as 
count and percentage, and the differences were tested using the Chi-square test or Fisher's 
exact test when appropriate. DFS was calculated from the date of ovarian cancer resection to 
the time of proven recurrence or death. OS was calculated from the date of ovarian cancer 
resection until the time of death from any cause or of the latest follow-up. Five-year DFS and 
OS were estimated using the Kaplan-Meier method. The effect difference between factors was 
determined by the Log-rank test. Age, BMI, number of births, and FIGO staging was assessed 
as a prognostic factor for OS and DFS in Cox regression analysis. The reported p-values were 
two-sided, and p-values <0.05 were considered statistically significant. All data were 




      We analyzed the medical records of 160 patients HGSOC. The median age was 56 
years (26–84); the median age of menarche was 13 (12–16); the median number of births was 
3 (0–11). Right-sided ovarian cancer was present in 53.8% (86/160) of the included patients. 
The clinical and pathologic characteristics of the right-sided and left-sided ovarian cancer 
patients are summarized in Table 1. According to patients’ characteristics, at right sided group 
74.4% and 67.6% left sided group BMI were ≥ 25. In addition, 66.3% of right sided tumor 
patients and 75.4% of left sided tumor patients were married; 69.8% of right sided tumor 
patients and 60.8% of left sided tumor patients were postmenopausal. There was no statistical 
significance in the distribution of these characteristic features. The patients were 
homogeneously distributed. 
      A higher percentage of patients with right-sided cancers had FIGO stage 3 compared 
with left-sided cancer patients (59.3% vs. 28.4%, p < 0.001). The percentages of the lymph 
node involvement in right-sided and left-sided ovarian cancer patients showed significant 
difference (27.9% vs. 9.5%; p = 0.003).  
 
Table 1. Clinicopathological characteristics of right- and left-sided ovarian cancer 
 
Characteristics  All 
 Right-sided 
cancer  Left-sided cancer p 
    (n=160) n (%)   n (%)     
Age 
       
≤ 50 
 












       
< 25 
 











No of birth 
      
≤ 2 
 












      










      
Single 
 












       












      









Lymph node  
      
Positive 
 





Negative 129 62 (72.1)   67 (90.5)     
BMI — body mass index; FIGO — the International Federation of Obstetrics and 
Gynecology 
       
Adjuvant chemotherapy 
      Among the 160 patients, 147 patients received adjuvant chemotherapy. In right-sided 
ovarian cancers, 79 (91.9%) patients received adjuvant chemotherapy, and in the left-sided 
ovarian cancers, 68 (91.9%) patients received adjuvant chemotherapy. There was no 
significant difference in treatment regimens between right- and left-sided ovarian cancers. 
Adjuvant chemotherapy is listed in Table 2. 
 












    (n = 86)   (n = 74)     
Treatment model 
    
0.994 




     Adjuvant CT 79 (91.9)   68 (91.9)     
CT — chemotherapy 
     
 
Survival analysis by tumor location 
      The Kaplan-Meier survival curves demonstrated a significant difference in the 5-year 
DFS rates between right and left-sided cancers for all stages (44.6% vs. 78.5%, p < 0.001) 
(Fig. 1). Also, there was a significant difference in the 5-year OS rates between the two 




Figure 1. Five-year disease-free survival rate of left sided over cancer and right sided over 






Figure 2. Five-year overall survival rate of left sided over cancer and right sided over cancer 
at diagnosis 
 
Details of recurrence 
      Postoperative recurrence occurred in 56 patients, 41 of whom had right-sided ovarian 
cancer, and 15 of whom had left-sided ovarian cancer (47.7% vs. 20.3%, p < 0.001). 
 
Multivariate analysis 
      Several variables were significant predictors of outcomes in the multivariate survival 
models (Tab. 3–4). According to multivariate analyses, the FIGO staging of patients makes a 
significant difference in DFS and OS.  
 
Table 3. Multivariate adjusted Cox model for 5-year disease-free survival 
 
  
Variables                                     5-year DFS       
      HR (95% CI) p value   
Age (≤ 50, > 50) 
 




0.6 (0.2–1.4) 0.206 
 
Tumor location 
(Right, Left) 0.6 (0.3–1.1) 0.05 
 
FIGO (1–2, 3)   6.2 (3.1–12.5) < 0.001   
 HR — hazard ratio; CI — confidence interval; DFS — disease-free survival; FIGO — the 
International Federation of Obstetrics and Gynecology 
 
Table 4. Multivariate adjusted Cox model for 5-year overall survival 
 
Variables                                       5-year OS     
      HR (95% CI) p value 
Age (≤ 50, > 50) 
 
0.9 (0.6–1.4) 0.641 
BMI (< 25, ≥ 25) 
 
0.6 (0.4–0.9) 0.007 
Menopausal status 
 
2.1 (1.3–3.4) 0.004 
Tumor localization (Right, Left) 0.7 (0.5–0.9) 0.033 
    





      In the present study, we enrolled 160 patients with HGSOC ovarian carcinoma, and 
we divided into two groups originating from the right or left ovary. It was significant that 
right-sided ovarian cancers are worse disease-free survival and overall survival in five years 
than left-sided ovarian cancers. Numbers of right and left-sided ovarian tumors were 
homogenous and chosen from two centers consecutively. 
      Increased survival rate at left-sided ovarian cancers than right-sided ovarian cancers 
was studied before by Roychoudhuri et al. [12]. This study contains not only ovarian cancer 
lateralization also compares five major paired organs of the body. They investigated five-year 
survival rates and left-sided ovarian cancer results were significantly higher than the right-
sided disease, but the difference was not significant. In this study, both ovarian epithelial and 
germ-cell cancers were included, and the excess of right-sided ovarian germ-cell cancers was 
evident in most age-groups; this could have masked the significance. In addition, stage 4 
disease were included to patient population. In our study all patients are chosen from HGSOC 
and we excluded metastatic disease. 
      Except for ovarian cancers, the presence of metastases in the contralateral organ at 
first diagnosis is infrequent. Reason for late presentation ovarian cancers occur after 
metastasis to the contralateral ovary; both ovaries are mostly involved during the presentation. 
This hypothesis thought to be the reason for obscuring the original primary laterality. 
      Right-sided lateralization of ovarian cancers was consistent with a study performed by 
Dane et al [13]. This trial included 221 women diagnosed with ovarian cancer; 130 on the 
right side and 91 on the left side who went under systematic pelvic laparotomy 
lymphadenectomy. The numbers of lymph nodes were significantly higher on the right side 
than the ones on the left side. The reason for this could be from partial functional immune 
asymmetry [14]. Our study's findings, which are consistent with those data of the literature, 
show that there is an asymmetry of ovarian cancer behaviors that are more aggressive on the 
right side.  
      Asymmetry of delayed-type hypersensitivity reaction was reviewed in the left and 
right paws of mice by Gontova et al [15]. The immune reaction was more manifested in the 
left paw rather than the right paw of all mice and concluded that it is determined by the 
functional asymmetry of regional lymph nodes. This result is verified by Erdem et al [16]. 
The tuberculin skin test is applied both left and right forearms of participants previously 
sensitized by the BCG vaccine. The reaction was greater on the left side of the body. The 
stronger cell-mediated immune activity on the left side may be associated with the blocking of 
the metastatic invasion of cancer cells and better disease-free survival and overall survival 
rates at left-sided ovarian cancer. This theory could explain better survival results of left 
ovarian cancers than right ovarian cancers and consistent with our findings. 
      David H. Brewster et al., (2007) and The Surveillance, Epidemiology, and End Results 
(SEER) Program at 2005 [8] have observed left-sided cutaneous melanomas are more often in 
several different populations. One of the theories to explain laterisation was excess of left-
sided tumors might arise from differential migration of melanocytes from the neural crest in 
the embryo. Asymmetric immune reactions are mentioned above this article. Melanoma 
reaction could be more powerful to exposure of sunlight at left side and end up on excess of 
left sided melanomas [7, 8]. 
      There is strong evidence that that tumor subsite location differences at colon cancers 
are associated with prognosis and treatment implications and an independent risk factor for 
mortality.  Wray et al. [17], analyzed 87,586 cases; 48% had tumors located in the proximal 
colon, whereas 10% had transverse colon cancer, 42% rectosigmoid colon. In this study, left-
sided colon cancers were observed to have lower tumor grade and independently decreased 
mortality compared with right-sided tumors. This data was verified by Benedix et al. [18], at 
2011; 53% had RCC, and 47% had LCC followed for five years. Tumors of the RCC 
displayed more aggressive tumor growth patterns than LCC. This trial showed that colonic 
subsite provides additional prognostic information. In our study, we demonstrated the 
prognostic importance of tumor localization of ovarian cancers the same as colon cancer 
survival dataset. Similar to colon cancer our study showed us ovarian cancers should be 
evaluated differently from which side tumor arises. DFS in five years was significantly longer 
at left-sided ovarian cancers, and additionally, overall survival was shorter at right-sided 
ovarian cancers. 
      In the cancer of testicles which are embryogenic equivalents of ovaries, had same 
asymmetry. Stone J.M. et al. [19], found 54% of testicular tumors overall were right-sided. 
Seminomas, yolk sac tumors and teratomas were more right-sided malignancies than average 
(p = 0.02). They explained reason of this asymmetry might be left testis usually hangs lower 
than right testis, thus more susceptible to trauma. Roychoudhuri R et al. [12], found that 
testicular cancers were more often in the right side when compared with the left side. In 
addition, left sided testis cancer had better OS than right sided tumor statistical significantly 
(p < 0.05). Lateralization that is noted at testicular cancers are similar to our findings of 
ovarian cancer. We found DFS and OS were significantly shorter at right-sided ovarian 
cancers. Embryogenic cell distributions or molecular feature could cause this asymmetry. 
Either immunity at left side might be stronger than right side, that blocks carcinogenesis. 
      Our study has several limitations; patients were collected from two hospitals, and 
surgical operations were performed by different surgeons. But operations were optimal, and 
no residual disease was seen. The number of one-sided onset ovarian cancer was less than we 
expected. Reason of this is the primary tumor could be difficult to define as right or left ovary 
in the first diagnosis due to the metastasis to the opposite ovary.  Despite the limited number 
of ovarian cancers in our study, it was statistically significant that lateralization seems to be 
important in disease-free survival and overall survival rates in five years. 
   
CONCLUSIONS 
      In summary, tumor location within the ovarian cancer is a prognostic factor for stage-
3 HGSOC. This situation raises this question: ‘Should we perform more aggressive surgical 
approaches at right-sided HGSOC?' and/or ' Right sided HGSOC needed more often follow 
up and prolonged treatments?'. This finding could be useful for stratifying patients to 
determine treatment strategies at diagnosis if supported by further prospective studies. 
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